Human papillomavirus vaccine in adolescent women: A 2012 update

Current Opinion in Obstetrics and Gynecology

Volumn 24, Issue 5, 2012, Pages 305-310

  Etter, Dillon J ^a   Zimet, Gregory D ^a   Rickert, Vaughn I ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adolescent; human papillomavirus; vaccine; women

Indexed keywords

WART VIRUS VACCINE;

AGE; CANCER IMMUNIZATION; CANCER PREVENTION; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; PAPILLOMAVIRUS INFECTION; PATIENT COMPLIANCE; POVERTY; PRIORITY JOURNAL; RACE; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER;

ADOLESCENT; COMMUNICATION; FEMALE; HEALTHCARE DISPARITIES; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIAN-PATIENT RELATIONS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84866412725     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283567005     Document Type: Review

References (75)

1. Forhan SE, Gottlieb SL, Sternberg MR, et al. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics 2009; 124:1505-1512.
2. Munoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111:278-285. (Pubitemid 38924707)
3. National Cancer Institute. Fact Sheet: HPV and Cancer. Bethesda, MD: National Cancer Institute (US); 2012. Retrieved from: http://www.cancer. gov/cancertopics/factsheet/Risk/HPV.
4. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907. (Pubitemid 47371147)
5. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199:805-814.
6. Middleman AB. New adolescent vaccination recommendations and how to make them 'stick'. Curr Opin Pediatr 2007; 19:411-416. (Pubitemid 47075621)
7. National Cancer Institute. Fact Sheet: Human Papillomavirus (HPV) Vaccines. Bethesda, MD: National Cancer Institute (US); 2011. Retrieved from: http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine.
8. CDC. HPV vaccine-questions answers. Atlanta, GA: Centers for Disease Control Prevention (US); 2011. Retrieved from: http://www.cdc.gov/vac cines/vpd-vac/hpv/vac-faqs.htm.
9. FDA. Highlights of prescribing information. Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]. Silver Spring, MD: US Food Drug Administration; 2011. Retrieved from: http://www. fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM111263.pdf.
10. CDC. National and State Vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1117-1123.
11. Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program, 2011. Canberra, Australia: Australian Government Department of Health and Ageing; 2011.
12. NHS. Childhood immunizations: human papillomavirus (HPV) immunisation uptake rates, in Child Health 2011, Edinburgh, Scotland: ISD Scotland (Information Services Division); 2011.
13. ECCA. HPV vaccination across Europe. Brussels, Belgium: European Cervical Cancer Association; 2009.
14. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health 2011; 49:467-475.
15. Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review meta-analysis. BMC Infect Dis 2011; 11:13-29.
16. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA 2007; 298:743-753. (Pubitemid 47263157)
17. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27:5612-5619.
18. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29:8279-8284.
19. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 2012; 271:193-203.
20. Gold R, Naleway AL, Jenkins LL, et al. Completion and timing of the threedose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med 2011; 52:456-458.
21. Skinner SR, Robbins SCC. Voluntary school-based human papillomavirus vaccination: an efficient and acceptable model for achieving high vaccine coverage in adolescents. J Adolesc Health 2010; 47:215-218.
22. LaMontagne DS, Barge S, Thi Le N, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low-and middle-income countries. Bull World Health Org 2011; 89:821-830.
23. Penny M, Bartolini R, Mosqueira NR, et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011; 29:5022-5030.
24. Marlow LAV. HPV vaccination among ethnic minorities in the UK: knowledge, acceptability and attitudes. Br J Cancer 2011; 105:486-492.
25. Olshen Kharbanda E, Stockwell MS, Colgrove J, et al. Changes in Tdap and MCV4 vaccine coverage following enactment of a statewide requirement of Tdap vaccination for entry into sixth grade. Am J Public Health 2010; 100:1635-1640.
26. Dempsey AF, Schaffer SE. Human papillomavirus vaccination rates and state mandates for tetanus-containing vaccines. Prev Med 2010; 52:268.
27. Brewer NT, Gottlieb SL, Reiter PL, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 2011; 38:197-204.
28. Guerry SL, De Rosa CJ, Markowitz LE, et al. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. Vaccine 2011; 29:2235-2241.
29. Hughes CC, Jones AL, Feemster KA, Fiks AG. HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr 2011; 11:74-83.
30. Taylor LSD, Hariri S, Sternberg M, et al. Human papillomavirus vaccine coverage in the United States. National Health and Nutrition Examination Survey, 2007-2008. Prev Med 2011; 52:398-400.
31. Smith LM, Brassard P, Kwong JC, et al. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an ontario cohort of grade 8 girls. BMC Public Health 2011; 11:645-656.
32. Liddon NC, Hood JE, Leichliter JS. Intent to receive HPV vaccine and reasons for not vaccinating among unvaccinated adolescent and young women: findings from the 2006-2008 National Survey of Family Growth. Vaccine 2012; 30:2676-2682.
33. Chou B, Krill LS, Horton BB, et al. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol 2011; 118:14-20.
34. Schluterman NH, Terplan M, Lydecker AD, Tracy JK. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine 2011; 29:3767-3772.
35. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009; 84:864-870.
36. Viera AJ, Rowe-West B, Grimshaw A, et al. The HPV vaccine: are dosing recommendations being followed? Vaccine 2011; 29:2548-2554.
37. Hirth JM, Tan A, Wilkinson GS, Berenson AB. Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer 2012. [Epub ahead of print]
38. Chandra A, Martinez GM, Mosher WD, et al. Fertility, family planning, and reproductive health of US women: data from the 2002 National Survey of Family Growth. Vital Health Stat 2005; 25:1.
39. Gold R, Naleway AL, Jenkins LL, et al. Completion and timing of the threedose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med 2011; 52:456-458.
40. De Visser R, Waites L, Parikh C, Lawrie A. The importance of social norms for uptake of catch-up human papillomavirus vaccination in young women. Sex Health 2011; 8:330-337.
41. Jacobson Vann J, Szilagyi P. Patient reminder and recall systems to improve immunization rates. Cochrane Database Syst Rev 2005; 3.
42. Szilagyi PG, Schaffer S, Barth R, et al. Effect of telephone reminder/recall on adolescent immunization and preventive visits: results from a randomized clinical trial. Arch Pediatr Adolesc Med 2006; 160:157-163. (Pubitemid 43213861)
43. Szilagyi PG, Humiston SG, Gallivan S, et al. Effectiveness of a citywide patient immunization navigator program on improving adolescent immunizations and preventive care visit rates. Arch Pediatr Adolesc Med 2011; 165:547-553.
44. Kharbanda EO, Stockwell MS, Fox HW, et al. Text message reminders to promote human papillomavirus vaccination. Vaccine 2011; 29:2537-2541.
45. CTIA. CTIA-The Wireless Association. Wireless Quick Facts. 2011 [06 May 2012]. Available from http://www.ctia.org/media/index.cfm/AID/10323.
46. Keenan K, Hipwell A, Stepp S. Race and sexual behavior predict uptake of the human papillomavirus vaccine. Health Psychol 2012; 31:31-34.
47. Bastani R, Glenn BA, Tsui J, et al. Understanding suboptimal human papillomavirus vaccine uptake among ethnic minority girls. Cancer Epidemiol Biomarkers Prev 2011; 20:1463-1472.
48. Niccolai LM, Mehta NR, Hadler JL. Racial/ethnic and poverty disparities in human papillomavirus vaccination completion. Am J Prev Med 2011; 41:428-433.
49. Palli SR, Mehta S, Aparasu RR. Prevalence and predictors of human papillomavirus vaccination in adolescent girls. J Am Pharm Assoc 2012; 52:52-58.
50. Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med 2012; 42:44-52.
51. Dempsey AF, Schaffer SE, Cohn LM. Follow-up analysis of adolescents partially vaccinated against human papillomavirus. J Adolesc Health 2012; 50:421-423.
52. Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008; 113 (S10):2855-2864.
53. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a universitybased health system. Vaccine 2010; 28:989-995.
54. Dempsey A, Cohn L, Dalton V, RuffinM. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine 2011; 29:528-534.
55. Gottlieb SL, Brewer NT, Sternberg MR, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health 2009; 45:430-437.
56. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010; 126:425-433.
57. Rand CM, Humiston SG, Schaffer SJ, et al. Parent and adolescent perspectives about adolescent vaccine delivery: Practical considerations for vaccine communication. Vaccine 2011; 29:7651-7658.
58. Goff SL, Mazor KM, Gagne SJ, et al. Vaccine counseling: a content analysis of patient-physician discussions regarding human papilloma virus vaccine. Vaccine 2011; 29:7343-7349.
59. Verhoeven V, Baay MFD, Baay PE, et al. Everything you always wanted to know about HPV (but could not ask your doctor). Patient Educ Couns 2010; 81:101-105.
60. Hopfer S, Clippard JR. College women's HPV vaccine decision narratives. Qual Health Res 2011; 21:262-277.
61. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theoryinformed, systematic review. Prev Med 2007; 45:107-114. (Pubitemid 47348081)
62. Cassidy B, Schlenk EA. Uptake of the human papillomavirus vaccine: a review of the literature and report of a quality assurance project. J Pediatr Health Care 2012; 26:92-101.
63. Rosenthal S, Weiss TW, Zimet GD, et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine 2011; 29:890-895.
64. McRee A-L, Reiter PL, Gottlieb SL, Brewer NT. Mother-daughter communication about HPV vaccine. J Adolesc Health 2011; 48:314-317.
65. Gindi M, Oravitz P, Sexton R, et al. Unreliability of reported tetanus vaccination histories. Am J Emerg Med 2005; 23:120-122. (Pubitemid 40349208)
66. Irving SA, Donahue JG, Shay DK, et al. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27:6546-6549.
67. Shenson D, DiMartino D, Bolen J, et al. Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program. Vaccine 2005; 23:1015-1020. (Pubitemid 40037650)
68. Skull SA, AndrewsRM, Byrnes GB, et al. Validity of self-reported influenza and pneumococcal vaccination status among a cohort of hospitalized elderly inpatients. Vaccine 2007; 25:4775-4783. (Pubitemid 46818615)
69. Stupiansky NW, Zimet GD, Cummings T, et al. Accuracy of self-reported human papillomavirus vaccine receipt among adolescent girls and their mothers. J Adolesc Health 2012; 50:103-105.
70. Kharbanda EO, Stockwell MS, Fox H, et al. The role of human papillomavirus vaccination in promoting delivery of other preventive and medical services. Acad Pediatr 2011; 11:326-332.
71. Kost K, Henshaw S, Carlin L. US Teenage pregnancies, births and abortions: National and state trends and trends by race and ethnicity. Washington, DC: Guttmacher Institute; 2010.
72. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007; 116:1488-1496. (Pubitemid 47480640)
73. Mullins TLK, Zimet GD, Rosenthal SL, et al. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med 2012; 166:82-88.
74. Kahn JA, Xu J, Zimet GD, et al. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health 2012; 50:464-470.
75. Schuler CL, Reiter PL, Smith JS, Brewer NT. Human papillomavirus vaccine and behavioural disinhibition. Sex Transm Infect 2011; 87:349-353.